Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

24.04.24	Biogen Q1 Adj. EPS Tops Estimates, But Sales Miss; Reaffirms FY24 Outlook (RTTNews)
01.04.24	Eisai Submits Leqembi SBLA For IV Maintenance Dosing In Early Alzheimer's Disease (RTTNews)
06.03.24	New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy (GlobeNewswire)
04.03.24	Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting (GlobeNewswire)
23.02.24	Biogen's Qalsody Receives Positive Opinion From CHMP (RTTNews)
23.02.24	Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP (GlobeNewswire)
13.02.24	Biogen Sees Higher Adj. EPS, Weak Revenues In FY24; Stock Down In Pre-market (RTTNews)
13.02.24	Biogen Inc. Q4 Profit Decreases, misses estimates (RTTNews)
13.02.24	Biogen's Skyclarys Approved In Europe For Friedreich's Ataxia Treatment (RTTNews)
12.02.24	Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia (GlobeNewswire)
09.02.24	Aptar Inks Enterprise Agreement With Biogen (RTTNews)
31.01.24	Biogen Decides To Discontinue Development Of Alzheimer's Drug Aduhelm (RTTNews)
31.01.24	Biogen to Realign Resources for Alzheimer's Disease Franchise (GlobeNewswire)
19.12.23	Biogen Says European Commission Revokes Marketing Authorizations For Generic Versions Of TECFIDERA (RTTNews)
19.12.23	Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission (GlobeNewswire)
15.12.23	Biogen's SKYCLARYS Gets CHMP Recommendation For Marketing Authorization (RTTNews)
15.12.23	CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease (GlobeNewswire)
14.12.23	Sage Therapeutics, Biogen Announce Availability Of ZURZUVAE In U.S. For PPD In Women (RTTNews)
14.12.23	ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. (GlobeNewswire)
08.11.23	Biogen Inc. Q3 Earnings Summary (RTTNews)
06.11.23	Biogen Appoints Monish Patolawala to its Board of Directors (GlobeNewswire)
25.10.23	Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional (GlobeNewswire)
25.10.23	EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITI... (PR Newswire)
25.10.23	New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease (GlobeNewswire)
24.10.23	LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023 (PR Newswire)
19.10.23	Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting (GlobeNewswire)
29.09.23	FDA Approves Biogen's Tofidence (RTTNews)
29.09.23	FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA® (GlobeNewswire)
26.09.23	Biogen Completes Acquisition Of Reata Pharmaceuticals; Plans To Update 2023 Guidance (RTTNews)
26.09.23	Biogen Completes Acquisition of Reata Pharmaceuticals (GlobeNewswire)
25.09.23	LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan (GlobeNewswire)
21.09.23	Reata Pharma Stockholders Approve Acquisition By Biogen (RTTNews)
06.09.23	Biogen Appoints Jane Grogan as Head of Research (GlobeNewswire)
05.08.23	Biogen : FDA Approves First Oral Treatment For Postpartum Depression (RTTNews)
05.08.23	FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder (GlobeNewswire)
28.07.23	Biogen To Buy Reata Pharma In Around $7.3 Bln Deal; Stocks Move In Premarket (RTTNews)
28.07.23	Biogen to Acquire Reata Pharmaceuticals (GlobeNewswire)
25.07.23	Biogen Q2 Results Top Estimates; Backs FY23 Outlook (RTTNews)
20.07.23	Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023 (PR Newswire)
20.07.23	Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023 (GlobeNewswire)
07.07.23	FDA Grants Traditional Approval To Eisai's Leqembi To Treat Adult Patients With Alzheimer's Disease (RTTNews)
07.07.23	FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease (GlobeNewswire)
07.07.23	FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease (PR Newswire)
30.06.23	New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy (GlobeNewswire)
29.06.23	FDA Panel Votes In Favor Of Ipsen's Palovarotene For Ultra-rare Bone Disease (RTTNews)
12.06.23	Biogen Announces Changes to Its Board of Directors (GlobeNewswire)
12.06.23	FDA Panel Recommends Full Approval For Biogen And Eisai's Alzheimer's Drug Leqembi (RTTNews)
10.06.23	FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease (GlobeNewswire)
10.06.23	FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease (PR Newswire)
09.06.23	FDA Advisors Evaluate Whether Alzheimer's Drug Leqembi Should Get Full Approval (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün
22.11.24		Starker Wochentag in Frankfurt: DAX bewegt sich zum Ende des Freitagshandels im Plus
22.11.24		Gewinne in Frankfurt: SDAX zum Handelsende freundlich
22.11.24		Gewinne in Frankfurt: LUS-DAX steigt schlussendlich
22.11.24		EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück
22.11.24		DAX-Handel aktuell: DAX nachmittags mit positivem Vorzeichen

22.11.24

Handel in Frankfurt: TecDAX letztendlich in Grün

22.11.24

Starker Wochentag in Frankfurt: DAX bewegt sich zum Ende des Freitagshandels im Plus

22.11.24

Gewinne in Frankfurt: SDAX zum Handelsende freundlich

22.11.24

Gewinne in Frankfurt: LUS-DAX steigt schlussendlich

22.11.24

EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück

22.11.24

DAX-Handel aktuell: DAX nachmittags mit positivem Vorzeichen